From Bench to Bedside: How In Vivo Models Guide Clinical Trial Design in Blood Cancers
In vivo models, particularly xenografts, are indispensable in translating laboratory discoveries into effective clinical therapies for blood cancers. These models provide critical insights that shape the design, dosing, and patient selection criteria of clinical trials.
Preclinical testing in animal models assesses not only the efficacy of novel compounds but also their toxicity, metabolism, and interaction with the immune system. This data helps define safe starting doses and schedules, identify biomarkers predictive of response, and evaluate potential drug combinations.
Xenograft models that faithfully replicate human leukemia or lymphoma enable researchers to observe tumor progression, metastasis, and resistance mechanisms in a living organism. This knowledge informs clinical endpoints, such as progression-free survival and minimal residual disease detection.
Moreover, preclinical models can identify subpopulations of patients likely to benefit from targeted therapies based on genetic or phenotypic characteristics, improving trial success rates and personalized medicine approaches.
Thus, in vivo studies form a vital bridge from bench to bedside, reducing risk and accelerating the delivery of innovative blood cancer treatments to patients.
References: Altogen.com Altogenlabs.com